At ASCO GU 2026, several studies advanced treatment strategies for kidney cancer, particularly in non–clear cell and previously treated RCC. Dr. Martin Voss discusses results from KEYNOTE-B61, supporting lenvatinib plus pembrolizumab as an effective option in papillary and other non–clear cell subtypes, as well as LITESPARK-011, which showed promising activity for lenvatinib plus belzutifan after prior immunotherapy. He also highlights the LITESPARK-022 adjuvant study and evolving discussions around treatment selection, toxicity, and patient risk profiles. Together, these findings underscore the expanding role of combination strategies and HIF inhibition across RCC treatment settings.
ARROS-1 Trial: Zidesamtinib Demonstrates Activity in TKI-Pretreated ROS1-Positive NSCLC
Nuvalent announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for zidesamtinib for
